Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dobrowolnie podpisał/podpisała zgodę na uczestnictwo i zobowiązuje się przestrzegać wymogów badania
- •Wiek: co najmniej 18 lat
- •Spodziewana długość życia: co najmniej 3 miesiące
- •Rozpoznany nowotwór złośliwy (zaawansowany lokalnie lub z przerzutami), który nie może być leczony operacją lub radioterapią
- •Poprzednie leczenie chemioterapią i/lub lekami immunologicznymi zgodnie z wytycznymi
- •Dostarczone próbki tkanki nowotworowej (zarchiwizowane lub świeża biopsja)
- •Co najmniej jeden zmierzalny guz według kryteriów RECIST V1.1
- •Dobry stan ogólny (ECOG 0-1) i prawidłowa funkcja organów (krew, wątroba, nerki, serce)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (39)
Beverly Hills Cancer Center
Beverly Hills, United States
City of Hope Cancer Center
Duarte, United States
Chao Family Comprehensive Cancer Care and Ambulatory Care
Irvine, United States
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
University of California Irvine Medical Center
Orange, United States
UCLA Santa Monica
Santa Monica, United States
University of Colorado Cancer Center
Aurora, United States
Yale University, Yale Cancer Center
New Haven, United States
Georgetown University Medical Center
Washington D.C., United States
Sylvester Comprehensive Cancer Center
Miami, United States
Sara Cannon Research Institute Lake Nona
Orlando, United States
Hematology - Oncology Associates of the Treasure Coast
Port Saint Lucie, United States
Northwestern University Feinberg School of Medicine
Chicago, United States
University of Iowa Hospital and Clinics
Iowa City, United States
Norton Cancer Institute
Louisville, United States
Massachusetts General Hospital
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
Memorial Sloan Kettering Cancer Center Head Neck Services
New York, United States
PRISMA Health/ITOR
Greenville, United States
Sarah Cannon - Tennessee Oncology
Nashville, United States
Oncology Consultants, P.A.
Houston, United States
University of Texas M.D. Anderson Cancer Center
Houston, United States
Virginia Cancer Specialists
Fairfax, United States
University of Washington Fred Hutchinson
Seattle, United States
Centre Léon Bérard
Lyon, France
Groupe Hospitalier Pitie-Salpetriere
Paris, France
Institut de Cancerologie de Ouest (ICO) - Saint-Herblain
Saint-Herblain, France
Institut Gustave Roussy
Villejuif, France
Fondazione del Piemonte per l'Oncologia IRCC Candiolo
Candiolo, Italy
IRCCS Istituto Clinico Humanitas, Cancer Center
Rozzano, Italy
National Cancer Center Hospital
Chūōku, Japan
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital de la Santa Creu I Sant Pau
Barcelona, Spain
Hospital Beata María Ana
Madrid, Spain
START Madrid / Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario 12 De Octubre
Madrid, Spain
START Madrid / Centro Integral Oncologico Clara Campal
Madrid, Spain
START Rioja
Piqueras, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Trial contact
Tara Barrineau
Colandra McDowell
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.